Moving from an apartment to a condo? Buying a condo unit is great time to reevaluate your standard of living. If you are ready to acquire your own home but can not afford a house, a condo could be a way for you to get into the real estate market . There are actually plenty of choices available for you . It entails the same process like shopping for a single-family home . You can also look for real estate websites online and find listings for condominiums available online .
When you want to consider buying a condominium, learn about what type of property and the ownership it requires . You have to read the agreement and other documents related to the management of the complex .
Before making decision on purchasing a real estate property as a resident, investor or a vacationer, try to check on some condominiums to make sure that you will move to a complex that suits your requirements. Create a list of what you would want to see in your condo like parking area, amenities, and look for units that meet up your criteria . Select locations which have convenient access to shopping, schools, hospital and more .
A condominium is like an apartment that you own. There are many reasons why buying a condo is better than an apartment, one the reasons is condo tend to increase prices at a slower rate, making them to be more affordable than any single -family houses and it can even free you from tasks like exterior maintenance that go along with acquiring a house. A condo unit can even make acquiring a vacation home more affordable. On the other hand, consider that most condominiums have monthly fees for repairs of your common property.
Remember to take your time in finding a condo unit for it will let you get the most out of your exciting home buying experience .
The most important thing we should remember is that condominium ownership requires enough funds. Never buy a home when you do not have enough money or do not spend more than what you have to avoid problems .
Related posts:
Should I Choose a Condominium or a Townhouse?
Is Condo Living Suitable For You?
Residential Investment Property ? Why To Buy Now
Condo Living Benefits
Zephyr Real Estate Agents Join Forces to Sell San Francisco
One of the most important things that you will need to do before taking out finance to purchase a new car is to work out how your repayments will fit in with your budget. This can be done quickly and easily with a car loan repayment calculator. This online tool allows you to work out how much your repayments will cost you each fortnight or month, so that you will know how much you can afford to borrow.
A car loan repayment calculator can be found online. Most auto loan websites will have a car loan repayment calculator that you will be able to access. By using an online calculator you will be able to play around with different loan amounts and finance options so that you can find the best one that suits your needs and your budget.
Working out auto financing repayments involves utilizing a rather complex formula and, unless you are aware of the formula for working out these repayments, this can often be a complicated process. Traditionally, in order to get these figures, customers were required to approach individual lenders for quotes. This was a time consuming task and one that often involved completing an initial loan request form containing all your details. An online car loan repayment calculator not only saves you a considerable amount of time when getting these figures, but it also allows you to get this information without having to complete a formal application.
There are many variable factors that can effect your scheduled loan repayments. When you use a car loan repayment calculator you can change these variables to work out which finance option is best suited to your budget. For example, the number of years you take your finance over will have an effect on the amount you repay. The longer the loan term the lower your repayments will be. Some people may be able to afford to borrow more for their new car if they take their loan over a 5 or 7 year term as opposed to a 3 year term, and a car loan repayment calculator will enable you to see the difference in your repayment amount for these various loan terms.
The first thing that you will need to consider before using a car loan repayment calculator is how much you can realistically afford to repay. Once you have established this amount you will be able to enter the relevant information into a car loan repayment calculator and adjust the figures accordingly until you get a repayment amount that fits in with your budget.
Most online calculators require similar information to be entered into them in order to get your scheduled repayment figures. To use a car loan repayment calculator you will need to enter in your loan amount, the interest rate applied to your finance, the length of your loan and the frequency of your repayments. At any time you can vary these different amounts in order to see how they will effect the amount that you will be required to repay on your finance so that you can choose the best option for you.
About the Author
Car Loans for ANY Credit!
We specialize in car loans for people with bad credit, approval is fast, easy and secure. New and used cars, SUV
There are a lot of myths about payday loans, and if you buy into them then you could miss out on getting the financing that you need. There is a conception that the interest rates are too high, for example, even though they are the lowest for a short term emergency loan that you can get. This article will clear up some of these misconceptions by describing how payday finance actually works.
How Pay Day Loans Work
As long as you are paid enough in a month to afford to get a pay day loan, you should have no problem in getting one. It usually only takes a few minutes to apply online, and the approval should come almost instantaneously. If you apply early enough, the money will then be transferred directly to your bank account, and the principal with interest will be taken out when you\?re next paid.
The only things other things you have to be concerned about are really just technical details. For example, you need to be 18 years old, or above. Also, you\?ll need a bank account of course, with a debit card attached to it in order to simplify the transactions.
No Credit Check
Payday lenders generally don\?t perform credit checks. The myth associated with this fact is that they are hoping their borrowers will not be able to pay back on time so that they can charge a lot more in interest.
The reason that this view is usually held is because when banks and other long term lenders check credit histories, that is taken as a sign that they are being responsible. Really though, they do it because they are going to have to make a loan which will partly be based on the borrower\?s income in a year or more, which of course nobody knows. A credit check just lets them make a better guess.
Having said that, it is certainly also useful that the absence of credit checks speeds up the process for payday finance. That\?s because loans of this type are often used in an emergency, so the money is going to be needed in a hurry. In other words, it is the borrower that benefits from this practice.
Loan Sharking?
Another common myth is that payday lenders are loan sharks, the implication being that they prey on poor people. When a company provides a service that a certain sector needs though, is that preying on them? Are people who want to buy a house being preyed on by mortgage providers, for example? Of course that is absurd, but it is the same reasoning.
So while it is true that poor people will be the ones taking out the loans usually, that\?s just a consequence of what they are used for. They\?re needed in emergency situations, for things like unpaid bills and car repairs. When people who are not poor, who have savings, come across problems like this they simply use their own money to pay for them so they don\?t need a loan.
Interest Rates Too High?
The most common misconception about pay day loans is that the interest rates are too high. For the borrower of course, they are always going to want to pay less in interest, and the lender is always going to want to charge more. The actual price is what each party is satisfied with.
By making a direct comparison between the amount of interest you have to pay for a payday loan and how much you have to pay for a normal bank loan though, you\?ll see that they are about the same. The whole problem comes about because people want long term APRs for short term loans, which would certainly increase their demand but the lenders would be making very little.
To learn more concering the true rates of interest for payday finance go to payday loans where John Breese also writes.
Related posts:
Finance: How Borrowers With Bad Credit Can Avail Of Quick Online Payday Loans (7/6/2011)
Finance: Learn About Payday (8/15/2010)
Loans: A Summary Of Loans For Bad Credit People Seek (7/15/2011)
Finance: Reasons For Getting A Payday Loan (7/12/2010)
PayDay Loans: I Need A Payday Loan Immediately For Last Minute Expenses (9/3/2010)
Stock market debacle doesn't necessarily signal a spectacular crash. The stock market may be reacting to prospects of a garden-variety recession.
Having lunch with Barry the other day (not salads) we got to talking about why it seems so hard for people to accept that the economic and stock market picture has grown darker over the last few weeks. What's so bad about a correction or a consolidation period? What's the harm in admitting that the Recovery is backsliding?
Skip to next paragraph Joshua M. Brown
Joshua has been managing money for high net worth clients, charitable foundations, corporations and retirement plans for more than a decade.
Recent posts
I always just assumed that the talking heads were perma-bullish for the money - most of them don't get paid unless you're fully invested (which is why there's a "let's put some money to work" bias in the asset management game). But Barry explained that it goes beyond that.
For starters, people have trouble saying one thing and then coming around and admitting that things have changed. There is a disconnect in the way our brains work which leads us to believe, on some level, that having new opinions is somehow a betrayal of our old opinions, even in the presence of fresh evidence. This is doubly true of those who predict and prognosticate in public for a living - they feel the need to be consistent lest they lose the role they've been cast in (perma-bull, doomsayer, wacky next-door neighbor etc).
In some cases, there's a political angle to it as well. I had clients who said they would never buy a stock as long as Obama was president...I wonder how they're doing these days. There are pundits who are funded by think tanks who pretend to be in the business of analysis but are really engaged in the art of slant and spin - positive or negative depending on who the paymaster is. There's a regular guest in Kudlow's menagerie who both cheerleaded the Bush stock market right off the cliff in 2007 only to predict the next Great Depression at the market's lows early in Obama's term.
But the main reason why so many people have such trouble reconciling improving or deteriorating economic data and stock market conditions is the Recency Effect. Barry says that because the wounds of 2008 are still so raw, people see the next 2008 in every setback. They forget that if we have a double-dip recession, it can be just a garden-variety recession. It doesn't have to be another apocalyptic, world-stopping calamity.
Let's say we do fall into a double dip as all that spent stimulus wears off, a regular recession without all the fireworks and institutional failures of the last one is not only possible, it is more likely.
In other words, think 1938 and not necessarily 2008.
Above is a killer annotated chart of the Dow Jones Industrial Average during the late 1930's I whipped up for you guys...
Without having the ancient economist battle of what caused the US economy to recede in 1937-1938 (Keynesians say the cessation of Federal spending, Monetarists say the Fed tightened too soon), we can all agree that FDR did pull back on the two main programs (Works Progress Administration and Public Works Administration) in the spring of 1937 and that the Fed was hawkish.
The stock market had been steadily recovering from the depths of 1932 (the Dow had hit 56 that year) and from early 1935 through 1937 it staged a furious two-year rally that took the average from 102 to 186, a double (sound familiar?). When the first signs of a slowdown hit, there was a brief sell-off, followed by a sharp recovery in stocks - and then as the data worsened and the Fed sat on its hands, off the cliff the markets went.
But it wasn't the end of the world, just a retracement of half the gains from the 1932 lows (but not all of them) and within 13 months, the economy regained its footing into the 1940's (with a little help from Hitler and Tojo).
The point is, the 1938 recession wasn't pleasant (unemployment jumped from 14.3% up to 19% that year) and the stock market certainly felt it, but then life went on. Most of the spectacular corporate failures and life-altering, forced migrations had already occurred in the early part of that decade, 1938 was a mere shadow of that.
It's too early to call a double dip recession as being imminent or inevitable, but it's never too early to mentally prepare for one.
My advice is to stop thinking 2008 and instead start thinking 1938 or 1953 or 1969 or 1981, you get the drift. Not every slowdown is a crash and we are in a secular bear market after all.
Add/view comments on this post.
--------------------------
The Christian Science Monitor has assembled a diverse group of the best economy-related bloggers out there. Our guest bloggers are not employed or directed by the Monitor and the views expressed are the bloggers' own, as is responsibility for the content of their blogs. To contact us about a blogger, click here. To add or view a comment on a guest blog, please go to the blogger's own site by clicking on the link above.
Parker Bohn III Bowling consoleParker Bohn III Bowling console
We had been covering gaming consoles like the Megatouch table top console which had touch screen features and also the $25,000 diamond and gold Nintendo game boy which was embezzled with yellow gold and diamond. However, bowling as a sport hasn?t been covered much except the Arcade console and the custom-installed bowling alley. Combining the 2 major concepts, and bringing back the 1950?s flavor is the 8-foot Parker Bohn III bowling console that brings alive the spirit of the alley, inside your home?s gaming room.
This console includes 10-inch tall bowling pins which can tumble just like the real ones with the help of the 3-inch steel and chrome bowling pucks, after travelling on the waxed Formica lane. Each pin can also rise up after being struck with the help of the magnetic electronic switching system placed below each one, which allows them to be back as they were formerly arranged. The scoring system included is the standard ABC scoring rules plus 6 other variations such as ?shadow? mode which dims the lights and raises the pins for a more competitive level of the sport.
Above the location of the pins, is a 27-inch LCD screen which displays your score card, suggests the best possible shots and angles along with commentary from bowling champion Parker Bohn III who could perhaps slip in a tip or two along the way. To bring alive the spirits of a real alley, there are two 30-Watt speakers and a single 100-Watt speaker that brings out the commentary, cheering sounds and all others which you could hear at a real alley. The benefit in this case is that all of this is being bought inside your gaming room and the comfort of your home, which cuts out your need to head to the alley every time your friends come over for a game.
To avail this console, you would have to shell $6000 for a single piece. But be sure to have enough space for this 8-foot long console, which weighs a slightly heavy 305 lbs. Rest assured, it will be your best companion on evenings with your buddies.
Via: Hammacher
Tags: Gaming,
virtual gaming technology,
realistic gaming console,
virtual gaming,
gaming console,
Bowling game console,
Bowling console,
Parker Bohn III pro-bowler console,
Parker Bohn III
FILE - In this July 28, 2010 file photo, New York Yankees' Alex Rodriguez reacts after he popped out in the second inning in a baseball game against the Cleveland Indians in Cleveland. Major League Baseball plans to interview Rodriguez as it investigates allegations the Yankees star took part in illegal celebrity poker games. ((AP Photo/Tony Dejak File)
FILE - In this July 28, 2010 file photo, New York Yankees' Alex Rodriguez reacts after he popped out in the second inning in a baseball game against the Cleveland Indians in Cleveland. Major League Baseball plans to interview Rodriguez as it investigates allegations the Yankees star took part in illegal celebrity poker games. ((AP Photo/Tony Dejak File)
FILE - In this March 25, 2010 file photo, New York Yankees' Alex Rodriguez reacts before striking out for the second time during a spring training baseball game against the Baltimore Orioles in Sarasota, Fla. Major League Baseball plans to interview Rodriguez as it investigates allegations the Yankees star took part in illegal celebrity poker games. (AP Photo/Brian Blanco)
CHICAGO (AP) ? Yankees star Alex Rodriguez will be interviewed by Major League Baseball as part of its investigation of his involvement in illegal poker games.
Rodriguez also faced questions about his gambling habits in 2005, when the Daily News reported he attended games at an underground poker club in New York. The slugging third baseman later acknowledged "it wasn't the right thing to do," and checked with MLB before holding a charity poker tournament the following year.
Now baseball wants to talk to him again.
"We take this very seriously and have been investigating this matter since the initial allegation," MLB said Wednesday in a statement. "As part of the investigation, the commissioner's office will interview Mr. Rodriguez."
Rodriguez is on the disabled list and wasn't with the team Wednesday night in Chicago.
"I don't really have any comment on that," manager Joe Girardi said before the Yankees played the White Sox. "Let baseball handle those things."
Star Magazine reported last month that several people saw A-Rod playing in games hosted at Hollywood hotels and residences. His publicist denied that Rodriguez participated.
Rodriguez's name is not mentioned in any court filings in relation to the games.
MLB said at the time that the report was the first the commissioner's office had heard about the accusation and baseball officials would look into the matter.
A spokesman for the Yankees declined comment when asked about Rodriguez on Wednesday. A message was left seeking comment from Richard Rubenstein, Rodriguez's publicist.
The 36-year-old Rodriguez had right knee surgery on July 14 but is expected to resume baseball activities on Thursday at the Yankees' facility in Florida. The three-time AL MVP is hitting .295 with 13 home runs and 52 RBIs this season.
Rodriguez ranks sixth on the career homer list with 626. He needs 137 to break Barry Bonds' all-time record.
___
Jay Cohen can be reached at http://www.twitter.com/jcohenap
First scorpion antivenom approved by FDAPublic release date: 4-Aug-2011 [ | E-mail | Share ]
Contact: Ann Cisneros ann@email.arizona.edu 520-626-7237 University of Arizona Health Sciences Center
12-year, international collaboration leads to FDA approval of antivenom to treat potentially fatal nerve-poisoning effects of scorpion sting. Drug produced in Mexico and tested in Arizona
The U.S. Food and Drug Administration today approved Anascorp, an antivenom produced in Mexico and tested in clinical trials conducted through the University of Arizona, for use in treating patients suffering the effects of scorpion sting.
"This is a historic event," said Dr. Leslie Boyer, director of the UA's VIPER Institute (Venom Immunochemistry, Pharmacology and Emergency Response Institute) and lead investigator on the clinical trials. "This is the first-ever drug approved for this use by the FDA; the first-ever drug that we are aware of being developed fully in Latin America and subsequently approved by the FDA; the first-ever scorpion antivenom proved effective under controlled clinical trials; and the first-ever antivenom with so few allergic reactions."
Nearly 2,000 patients in Arizona and Nevada have received the antivenom through the clinical trials conducted by Boyer, a pediatrician and toxicologist at the UA College of Medicine, and her colleagues.
Ultimately, these clinical trials brought together 27 Arizona hospitals, one hospital in Nevada and hundreds of volunteer health-care professionals, creating a first-of-its-kind outreach study network capable of conducting clinical trials of a treatment for a rare emergency.
The FDA approval is the culmination of a nearly 12-year collaboration of academic and clinical researchers with partners in business and industry from both sides of the U.S.-Mexico border. The benefits of this cooperative, international effort extend beyond U.S. patients.
Dr. Alejandro Alagn from the Institute of Biotechnology of the UNAM (National Autonomous University of Mexico) is an antivenom researcher, an adviser to Instituto Bioclon and an associate investigator at the UA VIPER Institute.
"We have been working together to test the Mexican antivenom under United States rules for close to 12 years, learning a lot from the process and learning from each other. This collaboration has really helped us produce a better product. For this project we needed to combine laboratory science, clinical science and a good manufacturer, and we needed to design a good clinical trial."
During the course of the clinical trials, support provided by the UNAM included developing new analytical techniques to measure the venom and antivenom in the blood of Arizona patients. In addition, scientists from the UNAM worked closely with Instituto Bioclon to ensure that manufacturing processes met the U.S. standards.
In Arizona, which has the highest concentration of dangerous bark scorpions in the U.S., about 8,000 scorpion stings occur each year. Several hundred of these result in serious nerve poisoning and require medical treatment. Nearly all of these patients are young children, whose breathing may be severely affected by the effects of the venom. Without antivenom, children stung by scorpions typically require heavy sedation and intensive supportive care and, often, a ventilator.
Decades ago, Arizonans had access to a different kind of antivenom that was produced at Arizona State University, but in 1999 the researcher's approaching retirement put an end to new production. No known replacement existed, and the critical need for antivenom was about to become urgent.
Boyer, who accompanied a National Geographic television crew filming of venomous creatures in Mexico in 1999, visited the Cuernavaca campus of the UNAM.
There, researchers were investigating the effects of a new antivenom made by Instituto Bioclon, based in Mexico City.
Having witnessed the use of the antivenom in children stung by scorpions in Mexico, Boyer was certain of the potential for this drug to help children in Arizona. But the safety and efficacy of the product, called Alacramyn in Mexico and later Anascorp in the U.S., had to be proved to the exacting standards of the FDA.
With a grant from the Office of Orphan Products Development of the FDA, a team of UA and UNAM faculty members conducted a study of the then-investigational drug in 2004 and 2005 at University Medical Center and Tucson Medical Center. The results were dramatic.
Recounted in the New England Journal of Medicine, the study showed that the antivenom alleviated the symptoms of nerve poisoning in children following a scorpion sting in a very short time. It also reduced the need for sedative medication dramatically and lowered levels of scorpion venom in the bloodstream.
A second study, conducted primarily at the San Carlos Hospital on Arizona's San Carlos Apache Indian Reservation, confirmed these findings and demonstrated that the treatment could safely be provided in a rural hospital, far from pediatric intensive care.
In 2004, the state of Arizona supplied additional research funds through the Arizona Department of Health Services and the Arizona Biomedical Research Commission, enabling the UA to expand its study.
Institutio Bioclon and U.S. partner Rare Disease Therapeutics, Inc. of Tennessee agreed to provide the antivenom to qualifying hospitals, while preparing a formal license application to the U.S. FDA.
Dr. Andreas Theodorou, a UA professor of pediatrics, chief medical officer of University Medical Center and a member of the research team, said, "This antivenom basically takes symptoms away in a very short time. What was a life-threatening disease that would put kids in the pediatric ICU has become, for most of them, an outpatient disease."
This collaboration among academic and business partners is poised to have a global impact. The research has attracted attention from numerous countries with venomous creatures that pose problems for people. Among these is Morocco, where Bioclon, assisted by Boyer and Alagn, plans to begin clinical trials on a similar antivenom to treat stings inflicted by North Africa's deadly scorpions.
"This project owes its success to the hard work and participation of thousands of people," Boyer said.
The consortium includes representatives of numerous state and federal agencies; multiple colleges and departments at the UA; 27 Arizona hospitals and one in Nevada; three poison control centers including the UA's Arizona Poison and Drug Information Center, which once housed the VIPER Institute; nearly 2,000 Arizona families; undergraduate students and graduate students on both sides of the border; ranchers and scorpion hunters; businessmen and factory workers; and academic colleagues on four continents.
The collaborators played significant roles, Boyer explained, adding, "The vast majority of these dedicated individuals received no compensation. They did it because it was in the best interest of the children, because it was the right thing to do."
###
Extra Info:
A video news release and interviews in English and Spanish are available for download at http://uanews.org/scorpion-fda
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
First scorpion antivenom approved by FDAPublic release date: 4-Aug-2011 [ | E-mail | Share ]
Contact: Ann Cisneros ann@email.arizona.edu 520-626-7237 University of Arizona Health Sciences Center
12-year, international collaboration leads to FDA approval of antivenom to treat potentially fatal nerve-poisoning effects of scorpion sting. Drug produced in Mexico and tested in Arizona
The U.S. Food and Drug Administration today approved Anascorp, an antivenom produced in Mexico and tested in clinical trials conducted through the University of Arizona, for use in treating patients suffering the effects of scorpion sting.
"This is a historic event," said Dr. Leslie Boyer, director of the UA's VIPER Institute (Venom Immunochemistry, Pharmacology and Emergency Response Institute) and lead investigator on the clinical trials. "This is the first-ever drug approved for this use by the FDA; the first-ever drug that we are aware of being developed fully in Latin America and subsequently approved by the FDA; the first-ever scorpion antivenom proved effective under controlled clinical trials; and the first-ever antivenom with so few allergic reactions."
Nearly 2,000 patients in Arizona and Nevada have received the antivenom through the clinical trials conducted by Boyer, a pediatrician and toxicologist at the UA College of Medicine, and her colleagues.
Ultimately, these clinical trials brought together 27 Arizona hospitals, one hospital in Nevada and hundreds of volunteer health-care professionals, creating a first-of-its-kind outreach study network capable of conducting clinical trials of a treatment for a rare emergency.
The FDA approval is the culmination of a nearly 12-year collaboration of academic and clinical researchers with partners in business and industry from both sides of the U.S.-Mexico border. The benefits of this cooperative, international effort extend beyond U.S. patients.
Dr. Alejandro Alagn from the Institute of Biotechnology of the UNAM (National Autonomous University of Mexico) is an antivenom researcher, an adviser to Instituto Bioclon and an associate investigator at the UA VIPER Institute.
"We have been working together to test the Mexican antivenom under United States rules for close to 12 years, learning a lot from the process and learning from each other. This collaboration has really helped us produce a better product. For this project we needed to combine laboratory science, clinical science and a good manufacturer, and we needed to design a good clinical trial."
During the course of the clinical trials, support provided by the UNAM included developing new analytical techniques to measure the venom and antivenom in the blood of Arizona patients. In addition, scientists from the UNAM worked closely with Instituto Bioclon to ensure that manufacturing processes met the U.S. standards.
In Arizona, which has the highest concentration of dangerous bark scorpions in the U.S., about 8,000 scorpion stings occur each year. Several hundred of these result in serious nerve poisoning and require medical treatment. Nearly all of these patients are young children, whose breathing may be severely affected by the effects of the venom. Without antivenom, children stung by scorpions typically require heavy sedation and intensive supportive care and, often, a ventilator.
Decades ago, Arizonans had access to a different kind of antivenom that was produced at Arizona State University, but in 1999 the researcher's approaching retirement put an end to new production. No known replacement existed, and the critical need for antivenom was about to become urgent.
Boyer, who accompanied a National Geographic television crew filming of venomous creatures in Mexico in 1999, visited the Cuernavaca campus of the UNAM.
There, researchers were investigating the effects of a new antivenom made by Instituto Bioclon, based in Mexico City.
Having witnessed the use of the antivenom in children stung by scorpions in Mexico, Boyer was certain of the potential for this drug to help children in Arizona. But the safety and efficacy of the product, called Alacramyn in Mexico and later Anascorp in the U.S., had to be proved to the exacting standards of the FDA.
With a grant from the Office of Orphan Products Development of the FDA, a team of UA and UNAM faculty members conducted a study of the then-investigational drug in 2004 and 2005 at University Medical Center and Tucson Medical Center. The results were dramatic.
Recounted in the New England Journal of Medicine, the study showed that the antivenom alleviated the symptoms of nerve poisoning in children following a scorpion sting in a very short time. It also reduced the need for sedative medication dramatically and lowered levels of scorpion venom in the bloodstream.
A second study, conducted primarily at the San Carlos Hospital on Arizona's San Carlos Apache Indian Reservation, confirmed these findings and demonstrated that the treatment could safely be provided in a rural hospital, far from pediatric intensive care.
In 2004, the state of Arizona supplied additional research funds through the Arizona Department of Health Services and the Arizona Biomedical Research Commission, enabling the UA to expand its study.
Institutio Bioclon and U.S. partner Rare Disease Therapeutics, Inc. of Tennessee agreed to provide the antivenom to qualifying hospitals, while preparing a formal license application to the U.S. FDA.
Dr. Andreas Theodorou, a UA professor of pediatrics, chief medical officer of University Medical Center and a member of the research team, said, "This antivenom basically takes symptoms away in a very short time. What was a life-threatening disease that would put kids in the pediatric ICU has become, for most of them, an outpatient disease."
This collaboration among academic and business partners is poised to have a global impact. The research has attracted attention from numerous countries with venomous creatures that pose problems for people. Among these is Morocco, where Bioclon, assisted by Boyer and Alagn, plans to begin clinical trials on a similar antivenom to treat stings inflicted by North Africa's deadly scorpions.
"This project owes its success to the hard work and participation of thousands of people," Boyer said.
The consortium includes representatives of numerous state and federal agencies; multiple colleges and departments at the UA; 27 Arizona hospitals and one in Nevada; three poison control centers including the UA's Arizona Poison and Drug Information Center, which once housed the VIPER Institute; nearly 2,000 Arizona families; undergraduate students and graduate students on both sides of the border; ranchers and scorpion hunters; businessmen and factory workers; and academic colleagues on four continents.
The collaborators played significant roles, Boyer explained, adding, "The vast majority of these dedicated individuals received no compensation. They did it because it was in the best interest of the children, because it was the right thing to do."
###
Extra Info:
A video news release and interviews in English and Spanish are available for download at http://uanews.org/scorpion-fda
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uNy74GJZ_fMSR54WMe91lQeK3hGXQxORncUaRBDq2XiWvljplVQy9cOl8o4Q-56isJtIJ2AaXFiCXakvdeokvZ4Ry9xXRVLjQnKl8xThY=s0-d){kind=small}
Public release date: 4-Aug-2011
Share ]